Known now as the Republic of North Macedonia, TrialSite recently reported that this diverse Balkan nation was on the verge of approaching use of Ivermectin for addressing at least mild, early onset SARS-CoV-2 infection, the virus behind COVID-19. Soon after that article, Slovakia became the first EU-based nation to actually authorize formally the use of the drug for COVID-19. Now Lirim Shabani, director for this Balkan nation’s Agency for Medicines and Medical Devices (MALMED), informed local media there that shipments of the drug have arrived and will be stocked in pharmacies this week. As Eastern European nations will increasingly embrace the drug, over 50 clinical trials are ongoing with sophisticated meta-analyses from physicians and researchers on both sides of the Atlantic showing real efficacy for this well-known drug with an established safety record.
Various news sources in this diverse Balkan nation confirm this news. Various tweets in January had already called out that MALMED had authorized importation for use by prescription for COVID-19 cases. With nearly 2.1 million people North Macedonia, formerly part of Yugoslavia, join Slovakia and making the move to accept Ivermectin, formally, and offer the people there what a growing number of researchers and physicians demonstrate is a safe and effective treatment for at least early onset, mild COVID-19 cases. Importantly, in other jurisdictions, this isn’t the case—in the United States, the National Institutes of Health currently takes a neutral stance to the drug—they don’t recommend for or against for purposes of treating COVID-19 as they have declared they need to see more data.
Key Contact: Lirim Shabani, Director
Call to Action: TrialSite will continue to monitor the situation.